Qurient Co., Ltd.
KOSDAQ biotech spun off from Institut Pasteur Korea, developing oncology and antibiotic drugs plus a drug distribution business.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2008 and listed on KOSDAQ in 2016, Qurient Co., Ltd. is a drug development biotech spun off from the Institut Pasteur Korea to commercialize its research outcomes. Its pipeline includes the CDK7 inhibitor mocaciclib (Q901), the Axl/Mer/CSF1R triple inhibitor adrixetinib (Q702), the next-generation dual-payload ADC QP101, the antibiotic telacebec (Q203), and the atopic dermatitis drug Q301, alongside a prescription drug distribution business. The company is organized into an R&D division and a drug distribution division, co-develops Keytruda combination regimens with MSD, out-licensed telacebec to the TB Alliance in February 2023, and reported consolidated revenue of KRW 7.0 billion at end-2025 and KRW 9.1 billion at end-2024.
Products & technology
- Pharmaceutical distribution businessSale of prescription and over-the-counter drugs
Clinical trials
data.go.kr2 MFDS clinical trial authorisations · 2022–2023 (Phase 1/2 2)
- Phase 1/2Q901, 키트루다주2023-06-21
8 trial sites
- Phase 1/2Q702, 키트루다주2022-09-06
10 trial sites
R&D and key agreements
Source: DART corporate disclosureMocaciclib(Q901) · 난소암, 전립선암, 유방암, 자궁내막암, 결장직장암, 소세포폐암 또는 췌장암 · 1/2상 진행중(단독/병용) · CDK7 inhibitor in Phase 1/2 (monotherapy/combination) trials in the US and Korea; co-developed with MSD as a Keytruda combination and used as the basis for the QP101 ADC
QP101 · 고형암 · 비임상(단독) · Next-generation dual-payload ADC based on a topoisomerase 1 inhibitor, in preclinical stage
Adrixetinib(Q702) - 진행형 고형암 · 진행형 고형암 · 1상 완료(단독), 미국 · Axl/Mer/CSF1R triple inhibitor
Adrixetinib(Q702) - 이식편대숙주질환/희귀혈액암 · 만성 이식편대숙주질환, 희귀 혈액암 · 1상 진행중(단독), 미국 · Axl/Mer/CSF1R triple inhibitor
Adrixetinib(Q702) - 병용 고형암 · 위암, 식도암, 간암, 자궁경부암 · 1B/2상 진행중(병용), 미국·한국 · Developed as a Keytruda combination under a co-development agreement with MSD
Adrixetinib(Q702) - 급성 골수성 백혈병 · 급성 골수성 백혈병 · 1상 진행중(단독), 미국 · Axl/Mer/CSF1R triple inhibitor
Telacebec(Q203) · 다제내성결핵, 부룰리 궤양, 한센병 · 2/3상 진행중(단독), 미국·호주·남아공 · Cytochrome bc1 inhibitor; out-licensed to the TB Alliance in February 2023, began a registrational trial in Australia for Buruli ulcer in July 2024, dosing about 40 patients in 2024 and 100 in 2025; expected to be Qurient's first approved drug once the expanded trial completes
Q301 · 아토피성피부염 · 2B상 완료(단독), 미국 · Topical 5-LO inhibitor; various commercialization strategies under discussion based on Phase 2 efficacy results
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition